Biotech venture capitalists have increasingly embraced the virtual model, seeding companies with promising assets, tiny staffs and a willingness to outsource. Now, as Reuters notes, a recent Big Pharma buyout signals that the idea is gaining steam among larger players. XO1, an Index Ventures-backed virtual outfit, became Johnson & Johnson’s ($JNJ) latest takeout target last month, is further affirmation that creating a small team devoted to a single asset can be the most efficient way to deploy cash in the biotech industry, according to some VCs. The XO1 exit follows a slew of similar deals, including Shire’s ($SHPG) $325 million acquisition of FerroKin BioSciences, which had become a poster child for so-called backyard biotechs.
https://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png 0 0 CAST ADMIN https://cancure.com/wp-content/uploads/2015/05/Cancure_Logo_Website_v01.png CAST ADMIN2015-04-10 12:56:202021-08-16 22:02:24Virtual biotechs a hit with investors and, increasingly, buyers